Keyword: AbbVie

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.

Taking over IL-23 inhibitor brazikumab marks a new endeavor for AstraZeneca, as does buying prescription drugs Zenpep and Viokace for Nestlé.

More than three-quarters of Sanofi's sales come from products over 10 years old—a quandary that can't be solved without M&A, Vantage says.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.

We're not gonna lie—Wednesdays at the J.P. Morgan Healthcare Conference feel a bit anticlimactic. But that doesn't mean the action has stopped.

Humira's best days may be past, but AbbVie could one day see $20 billion in combined sales for follow-ups Rinvoq and Skyrizi, CEO Rick Gonzalez said.

With AbbVie looking for growth post-Allergan merger, the drugmaker can tout new Skyrizi data topping Novartis' Cosentyx in clearing patients' skin.

The additional tax charge is related to the $1.64 billion breakup fee AbbVie paid Shire in its nixed $55 billion takeover bid five years ago.

After months of regulatory scrutiny, the EU has given AbbVie and Allergan's $63 billion merger its first go-ahead in anticipation of an FTC decision.